Richard Norton’s death: TGA review of unapproved peptides demanded

TVS News AI, editorially supervised, presents Richard Norton’s death: TGA review of unapproved peptides demanded.

A 75-year-old Australian actor has died – and suddenly, a small medical issue has become the focus of a debate over medicines and their approval. Richard Norton worked in the film industry as a fight choreographer, stuntman and martial arts expert.

According to The Guardian, Norton suffered cardiac arrest in March 2025 after an injection of CJC1295 and Ipamorelin. The peptides were prescription-only but not approved.

The case is relevant to people considering how strictly authorities regulate medical active ingredients: It could change the rules governing the use and marketing of these peptides. It is also important to consider how cautiously the possible consequences can be expressed.

What is established following Richard Norton’s death

The central trigger for the case was the injection of CJC1295 and Ipamorelin. Although the two substances were prescription-only, they had no approval. After they were administered, Richard Norton suffered cardiac arrest.

The coroner apparently does not view this case solely as a tragic individual tragedy. He has called for Australia’s TGA to review the unapproved peptides. This places not only the fatal incident at the center of attention, but also the question of how such substances should be handled in the future.

Why the case concerns the TGA

The report identifies stricter restrictions for the substances as a possible consequence. This is explicitly a possible development, not a decision already made. What is certain, however, is the call for a TGA review.

The combination of two details is particularly relevant: The peptides were prescription-only while simultaneously being not approved. The decision to use them therefore rested with the treating doctor and the user, even though the substances themselves did not have a regular approved status.

It is precisely this gap that could become the subject of the review following Norton’s death. For you as a patient, it is crucial to distinguish between a medically prescribed preparation and an approved medicine – a prescription alone does not automatically mean that an active ingredient has official approval.

A possible change to the rules – without a definitive answer

The case shows how quickly a medical individual case can become a regulatory issue. According to The Guardian, CJC1295 and Ipamorelin were prescription-only but were not approved as conventional medicines. Following Richard Norton’s cardiac arrest, the coroner therefore called for a TGA review.

It remains unclear whether this will result in a ban, stricter prescribing rules or other conditions. What is clear is that the authority could in future examine more closely how unapproved peptides are prescribed, made available and used. Norton’s death could therefore have an impact beyond the individual case on how these substances are handled.

What the case means for the safety of medical peptides

The report’s central message is sober: A prescription does not replace approval. As a result, anyone prescribed peptides should not automatically assume that all regulatory requirements have been satisfied. The case raises the question of how responsibly unapproved preparations should be handled.

The case could lead to stricter restrictions within Australia’s system. Exactly what these restrictions would look like remains open. The only certainty is that the coroner has initiated a TGA review of CJC1295 and Ipamorelin because of Richard Norton’s death.